JP2008536483A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536483A5
JP2008536483A5 JP2008500259A JP2008500259A JP2008536483A5 JP 2008536483 A5 JP2008536483 A5 JP 2008536483A5 JP 2008500259 A JP2008500259 A JP 2008500259A JP 2008500259 A JP2008500259 A JP 2008500259A JP 2008536483 A5 JP2008536483 A5 JP 2008536483A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nucleic acid
acid molecule
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500259A
Other languages
English (en)
Japanese (ja)
Other versions
JP4933527B2 (ja
JP2008536483A (ja
Filing date
Publication date
Priority claimed from GBGB0504767.5A external-priority patent/GB0504767D0/en
Application filed filed Critical
Publication of JP2008536483A publication Critical patent/JP2008536483A/ja
Publication of JP2008536483A5 publication Critical patent/JP2008536483A5/ja
Application granted granted Critical
Publication of JP4933527B2 publication Critical patent/JP4933527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008500259A 2005-03-08 2006-03-08 リポカリンタンパク質 Expired - Fee Related JP4933527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0504767.5A GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein
GB0504767.5 2005-03-08
PCT/GB2006/000820 WO2006095164A1 (en) 2005-03-08 2006-03-08 Lipocalin protein

Publications (3)

Publication Number Publication Date
JP2008536483A JP2008536483A (ja) 2008-09-11
JP2008536483A5 true JP2008536483A5 (enExample) 2009-04-30
JP4933527B2 JP4933527B2 (ja) 2012-05-16

Family

ID=34452020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500259A Expired - Fee Related JP4933527B2 (ja) 2005-03-08 2006-03-08 リポカリンタンパク質

Country Status (15)

Country Link
US (1) US20080254035A1 (enExample)
EP (1) EP1869074A1 (enExample)
JP (1) JP4933527B2 (enExample)
KR (1) KR20070118614A (enExample)
CN (1) CN101189257A (enExample)
AU (1) AU2006221859B2 (enExample)
BR (1) BRPI0609020A2 (enExample)
CA (1) CA2599540A1 (enExample)
EA (1) EA011816B1 (enExample)
GB (1) GB0504767D0 (enExample)
IL (1) IL185547A0 (enExample)
MX (1) MX2007010809A (enExample)
NO (1) NO20075068L (enExample)
UA (1) UA94221C2 (enExample)
WO (1) WO2006095164A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd86 길항제 다중-표적 결합 단백질
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
AU2011213678B2 (en) 2010-02-04 2015-01-29 Eisai Inc. Chlorotoxin polypeptides and conjugates and uses thereof
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
DK2606061T3 (da) * 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
CN104487587A (zh) 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
CN105189540A (zh) * 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーb細胞分化方法およびvsv−g偽型ウイルスベクターを用いる形質導入方法
AU2014296626B2 (en) 2013-07-29 2019-03-07 Regeneron Pharmaceuticals, Inc. Multipartite signaling proteins and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR20160079854A (ko) 2013-10-31 2016-07-06 프레드 헛친슨 켄서 리서치 센터 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
RS61223B1 (sr) 2013-12-20 2021-01-29 Hutchinson Fred Cancer Res Označeni himerni efektorski molekuli i njihovi receptori
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
CA2978186A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
JP6985934B2 (ja) 2015-04-29 2021-12-22 フレッド ハッチンソン キャンサー リサーチ センター 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
CR20180503A (es) 2016-04-14 2018-12-21 Hutchinson Fred Cancer Res Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
AU2018385699B2 (en) 2017-12-14 2024-08-15 Regeneron Pharmaceuticals, Inc. Daric interleukin receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP4268831A3 (en) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
CA3148027A1 (en) 2019-05-08 2020-11-12 2Seventy Bio, Inc. Cll-1 targeted immunotherapies
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
CN111979249B (zh) * 2020-07-28 2021-12-10 复旦大学附属眼耳鼻喉科医院 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364780A (en) * 1989-03-17 1994-11-15 E. I. Du Pont De Nemours And Company External regulation of gene expression by inducible promoters
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5362865A (en) * 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) * 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2002018571A2 (en) * 2000-08-31 2002-03-07 Zymogenetics, Inc. Human phermone polypeptides

Similar Documents

Publication Publication Date Title
JP2008536483A5 (enExample)
JP2009268467A5 (enExample)
JP2006149406A5 (enExample)
ES2612741T3 (es) Proteínas de fusión proteína n de un virus de la familia paramyxoviridae-proteína de interés
JP2013515057A5 (enExample)
JP2010529860A5 (enExample)
JP2013515055A5 (enExample)
JP2018510622A5 (enExample)
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
JP2013517783A5 (enExample)
JP2012505902A5 (enExample)
JP2009537143A5 (enExample)
JP2008507298A5 (enExample)
JP2012115277A5 (enExample)
JP2006502702A5 (enExample)
JP2021508672A5 (enExample)
JP2011528897A5 (enExample)
JP2025170319A (ja) Sars-cov-2阻害剤
JPWO2021116462A5 (enExample)
JP2010532656A5 (enExample)
CN116693673B (zh) 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用
JP2007535910A5 (enExample)
JP2012516140A5 (enExample)
F Nahhas et al. Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics
JP2020509770A5 (enExample)